Supplementary Tables from Integrated Human and Murine Clinical Study Establishes Clinical Efficacy of Ruxolitinib in Chronic Myelomonocytic Leukemia
Year: 2023
Type: supplementary-materials
Abstract: Supplementary Table S1 details the IWG response criteria for MDS/MPNs. Supplementary Table S2 summarizes grade 3 and 4 treatment-emergent toxicities. Supplementary Table S3 summarizes all recorded adverse events. Supplementary Table S4 summarizes the reasons for treatment discontinuation. Supplementary Table S5 details the baseline characteristics of patients from which patient-derived xenograft mice were generated.
Authors: Anthony M. Hunter, Hannah Newman, Amy E. Dezern, David P. Steensma, Sandrine Niyongere, Gail J. Roboz, Qianxing Mo, Onyee Chan, Aaron Gerds, David A. Sallman, William Dominguez-Viqueira, Christopher Letson, Maria E. Balasis, Markus Ball, Traci Kruer, Hailing Zhang, Jeffrey E. Lancet, Alan F. List, Mikkael A. Sekeres, Rami S. Komrokji, Eric Padron
Language: English
Subfield: Genetics (clinical)
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4361890438